PPAR : a dagger in the heart of the metabolic syndrome
Open accessThe DOI matches its Crossref record; 97 of the 100 references it cites were found in a registry or an index.
Abstract
Obesity is a growing threat to global health by virtue of its association with insulin resistance, glucose intolerance, hypertension, and dyslipidemia, collectively known as the metabolic syndrome or syndrome X. The nuclear receptors PPARalpha and PPARgamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively, and drugs that modulate these receptors are currently in clinical use. More recent work on the less-described PPAR isotype PPARdelta has uncovered a dual benefit for both hypertriglyceridemia and insulin resistance, highlighting the broad potential of PPARdelta in the treatment of metabolic disease. PPARdelta enhances fatty acid catabolism and energy uncoupling in adipose tissue and muscle, and it suppresses macrophage-derived inflammation. Its combined activities in these and other tissues make it a multifaceted therapeutic target for the metabolic syndrome with the potential to control weight gain, enhance physical endurance, improve insulin sensitivity, and ameliorate atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both overexpression and activation of PPARδ result in increased mitochondrial biogenesis in the absence of an increase in PGC-1α mRNA in skeletal muscle in vivo (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The finding that overexpression of PPARδ in skeletal muscle of transgenic mice does not result in an increase in PGC-1α mRNA led to the conclusion that the increase in mitochondria is mediated directly by PPARδ (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In contrast to the finding in mouse and rat skeletal muscle that PPARδ overexpression or activation does not result in an increase in PGC-1α mRNA, a number of studies have shown that PPARδ induces an increase in PGC-1α gene transcription, with a rapid increase in PGC-1α mRNA, in myotubes (19, 50, 51).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The regulation of PGC-1α expression by PPARδ differs markedly between skeletal muscle in vivo and myotubes in culture.”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Research works printed but not linked: 1
- [77]Lee, C.H., et al. 2006. PPAR delta is a potent insulin sensitizer. Proc. Natl. Acad. Sci. U. S. A. In press.
Cited by
Items 101–200 of 738
The next generation of PPAR drugs: Do we have the tools to find them?
SHEARER, B. G., & Billin, A. N. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.005 · Cited by 119
Hu, T., Lin, Q., Guo, T., Yang, T., Zhou, W., Deng, X., Yan, J.-K., Luo, Y., Ju, M., & Luo, F. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.08.021 · Cited by 113
Panlilio, L. V., Justinova, Z., & Goldberg, S. R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.003 · Cited by 108
“The functions of the β/δ subtype, are less well established, but it might be involved in regulation of metabolism and differentiation of keratinocytes, adipocytes and oligodendrocytes (Matsuura et al., 1999; Jehl-Pietri et al., 2000; Saluja et al., 2001; Barish et al., 2006).”
BackgroundSocial Isolation Affects the Development of Obesity and Type 2 Diabetes in Mice
Nonogaki, K., Nozue, K., & Oka, Y. (2007) · Endocrinology · doi:10.1210/en.2007-0296 · Cited by 115
Modulation of megakaryopoiesis and platelet production during inflammation
Couldwell, G. C., & Machlus, K. R. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.008 · Cited by 116
Nunn, A. V., Bell, J., & Barter, P. (2007) · Nuclear Receptor · doi:10.1186/1478-1336-5-1 · Cited by 108
AMPK and transcriptional regulation
McGee, S. (2008) · Frontiers in Bioscience · doi:10.2741/2907 · Cited by 101
Pourcet, B., Fruchart, J.-C., Staels, B., & Glineur, C. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.379 · Cited by 98
“PPAR-β/δ agonists seem to be indicated in the metabolic syndrome treatment [64].”
BackgroundGoing nuclear in metabolic and cardiovascular disease
Glass, C. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27913 · Cited by 111
Peroxisome Proliferators‐Activated Receptor (PPAR) Modulators and Metabolic Disorders
Cho, M.-C., Lee, K., Paik, S.-G., & Yoon, D.-Y. (2008) · PPAR Research · doi:10.1155/2008/679137 · Cited by 89
“Recent evidence indicates that PPARδ can also promote cellular lipid accumulation by increasing the expressions of genes that are involved in lipid uptake, and by repressing key genes that are involved in lipid metabolism, inflammation, atherosclerosis, obesity, fertility, and cancer [74, 75].”
BackgroundSalvadó, L., Barroso, E., Gómez-Foix, A. M., Palomer, X., Michalik, L., Wahli, W., & Vázquez‐Carrera, M. (2014) · Diabetologia · doi:10.1007/s00125-014-3331-8 · Cited by 105
Transcriptional control of mitochondrial biogenesis and its interface with inflammatory processes
Piantadosi, C. A., & Suliman, H. B. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.01.003 · Cited by 98
Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ‐deficient mice
Müller‐Brüsselbach, S., Kömhoff, M., Rieck, M., Meißner, W., Kaddatz, K., Adamkiewicz, J., Keil, B. R., KLOSE, K. J., Moll, R., Burdick, A. D., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601803 · Cited by 105
Nuclear receptors as drug targets for metabolic disease
Schulman, I. G. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.002 · Cited by 107
Lee, W.-S., & Kim, J. (2015) · PPAR Research · doi:10.1155/2015/271983 · Cited by 91
Controle da adipogênese por ácidos graxos
de Queiroz, J. C. F., Alonso‐Vale, M. I. C., Curi, R., & Lima, F. B. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000500011 · Cited by 104
Nuclear receptor signalling in dendritic cells connects lipids, the genome and immune function
Szatmari, I., & Nagy, L. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.160 · Cited by 87
“…for example, PPARa promotes fatty acid oxidation in the liver (Lefebvre et al, 2006), PPARg is indispensable for adipocyte differentiation and generally stimulates lipid storage (Willson et al, 2001), and PPARd is an important regulator of skeletal muscle lipid oxidation (Barish et al, 2006).”
BackgroundMultifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?☆
Balakumar, P., & Jagadeesh, G. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.07.003 · Cited by 102
A Missense Mutation in PPARD Causes a Major QTL Effect on Ear Size in Pigs
Ren, J., Duan, Y., Qiao, R., Yao, F., Zhang, Z., Yang, B. J., Guo, Y., Xiao, S., Wei, R., Ouyang, Z., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002043 · Cited by 101
“were highly expressed, whereas transcripts of other genes were almost absent in ear tissues (data not shown). Of the 4 genes, PPARD (peroxisome proliferator-activated receptor delta) is a ligand-modulated transcription factor belonging to the nuclear receptor superfamily and plays crucial roles in diverse biologically…”
BackgroundBerry, D. C., & Noy, N. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.07.002 · Cited by 100
PGC‐1α activation as a therapeutic approach in mitochondrial disease
Wenz, T. (2009) · IUBMB Life · doi:10.1002/iub.261 · Cited by 91
Retinoic Acid Treatment Increases Lipid Oxidation Capacity in Skeletal Muscle of Mice
Amengual, J., Ribot, J., Bonet, M. L., & Palou, A. (2008) · Obesity · doi:10.1038/oby.2007.104 · Cited by 98
The role of the endocannabinoid system in lipogenesis and fatty acid metabolism
Vettor, R., & Pagano, C. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.002 · Cited by 97
Cyclooxygenase-2 and Colorectal Cancer Chemoprevention: The β-Catenin Connection
Castellone, M. D., Teramoto, H., & Gutkind, J. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2233 · Cited by 97
Afif, H., Benderdour, M., Mfuna-Endam, L., Martel-Pelletier, J., Pelletier, J.-P., Duval, N., & Fahmi, H. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2151 · Cited by 84
“PPARβ/δ is fairly ubiquitous and seems to be important in lipid and energy homeostasis [ 7 ].”
BackgroundCardiac Protective Effects ofMoringa oleiferaSeeds in Spontaneous Hypertensive Rats
Randriamboavonjy, J. I., Loirand, G., Vaillant, N., Lauzier, B., Derbré, S., Michalet, S., Pacaud, P., & Tesse, A. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw001 · Cited by 95
Metabolic remodeling in hypertrophied and failing myocardium: a review
Peterzan, M. A., Lygate, C. A., Neubauer, S., & Rider, O. J. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00731.2016 · Cited by 95
“PPAR- / is expressed widely, upregulates cardiomyocyte FAO (36, 69), and improves insulin sensitivity (23).”
BackgroundActivation of PPARβ/δ Causes a Psoriasis-Like Skin Disease In Vivo
Romanowska, M., Reilly, L., Palmer, C. N. A., Gustafsson, M. C. U., & Foerster, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009701 · Cited by 86
OECD (2012) · OECD series on testing and assessment · doi:10.1787/9789264221352-en · Cited by 93
Serrano-Marco, L., Barroso, E., Kochairi, I. E., Palomer, X., Michalik, L., Wahli, W., & Vázquez‐Carrera, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2401-4 · Cited by 92
Maternal–Fetal Cholesterol Transport in the Placenta: Good, Bad, and Target for Modulation
Palinski, W. (2009) · Circulation Research · doi:10.1161/circresaha.109.194191 · Cited by 92
Metabolic shifts due to long-term caloric restriction revealed in nonhuman primates
Rezzi, S., Martin, F.-P. J., Shanmuganayagam, D., Colman, R. J., Nicholson, J. K., & Weindruch, R. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.02.008 · Cited by 77
“PPARδ and PPARγ agonists are also considered for this therapeutic approach (Barish et al., 2006; Robinson, 2008).”
Thulin, P., Wei, T., Werngren, O., Cheung, L. K., Fisher, R. M., Grandér, D., Corcoran, M., & Ehrenborg, E. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1311 · Cited by 91
“Upon ligand binding, PPARδ is activated and releases the anti-inflammatory transcriptional suppressor protein B cell lymphoma-6 (BCL-6), which leads to suppression of inflammatory gene expression (3,4).”
Koppen, A., Houtman, R., Pijnenburg, D., Jeninga, E. H., Ruijtenbeek, R., & Kalkhoven, E. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900209-mcp200 · Cited by 91
George, J., & Liddle, C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp700110z · Cited by 81
Coll, T., Álvarez-Guardia, D., Barroso, E., Gómez-Foix, A. M., Palomer, X., Laguna, J. C., & Vázquez-Carrera, M. (2010) · Endocrinology · doi:10.1210/en.2009-1211 · Cited by 90
Transcriptional Regulation of Hepatic Fatty Acid Metabolism
Guillou, H., Martin, P. G. P., & Pineau, T. (2008) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-1-4020-8831-5_1 · Cited by 90
Mandard, S., & Patsouris, D. (2013) · PPAR Research · doi:10.1155/2013/613864 · Cited by 90
de Lange, P., Farina, P., Moreno, M., Ragni, M., Lombardi, A., Silvestri, E., Burrone, L., Lanni, A., Goglia, F., de Lange, P., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6025fje · Cited by 79
James, G., Sluka, K. A., Blomster, L. V., Hall, L., Schmid, A. B., Shu, C. C., Little, C. B., Melrose, J., & Hodges, P. W. (2018) · European Spine Journal · doi:10.1007/s00586-018-5652-7 · Cited by 86
Kim, H. J., Ham, S. A., Kim, S. U., Hwang, J.-Y., Kim, J.-H., Chang, K. C., Yabe-Nishimura, C., Kim, J.-H., & Seo, H. G. (2008) · Circulation Research · doi:10.1161/circresaha.107.158477 · Cited by 77
Retinoid Metabolism and Diabetes Mellitus
Rhee, E., & Plutzky, J. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.3.167 · Cited by 85
Patsouris, D., Neels, J. G., Fan, W., Li, P.-P., Nguyen, M. T. A., & Olefsky, J. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.041665 · Cited by 84
Lu, C., & Cheng, S.-Y. (2009) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0107 · Cited by 83
“Its target genes are involved in FA oxidation, fuel switch, mitochondrial respiration, and thermogenesis (Barish et al. 2006, Furnsinn et al. 2007).”
Backgroundde Souza, M. O., Silva, L. S. E., Magalhães, C. L. D. B., de Figueiredo, B. B., Costa, D. C., Silva, M. E., & Pedrosa, M. L. (2012) · Nutrition Research · doi:10.1016/j.nutres.2012.10.001 · Cited by 83
Hollingshead, H. E., Killins, R. L., Borland, M. G., Girroir, E. E., Billin, A. N., Willson, T. M., Sharma, A. K., Amin, S., Gonzalez, F. J., & Peters, J. M. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm183 · Cited by 71
The Roles of Peroxisome Proliferator-Activated Receptors in the Metabolic Syndrome
Mansour, M. M. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00007-7 · Cited by 82
Peroxisome proliferator-activated receptors for hypertension
Usuda, D., & Kanda, T. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i8.744 · Cited by 82
Serrano-Marco, L., Rodríguez-Calvo, R., El Kochairi, I., Palomer, X., Michalik, L., Wahli, W., & Vázquez-Carrera, M. (2011) · Diabetes · doi:10.2337/db10-0704 · Cited by 78
Haro, D., Marrero, P. F., & Relat, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061386 · Cited by 81
Tsuchiya, K., Sakai, H., Suzuki, N., Iwashima, F., Yoshimoto, T., Shichiri, M., & Hirata, Y. (2007) · Endocrinology · doi:10.1210/en.2006-1371 · Cited by 80
Nuclear Receptors and Inflammatory Diseases
Wang, K., & Wan, Y.-J. Y. (2008) · Experimental Biology and Medicine · doi:10.3181/0708-mr-231 · Cited by 72
Yu, B.-C., Chang, C.-K., Ou, H., Cheng, K., & Cheng, J.-T. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn172 · Cited by 80
Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice
Bak, E., Kim, J., Choi, Y. H., Kim, J., Lee, D.-E., Woo, G., Cha, J., & Yoo, Y. (2013) · Clinical Nutrition · doi:10.1016/j.clnu.2013.03.013 · Cited by 79
Li, F., Luo, H., Xu, Z., Yang, Z., Du, G., Zhang, Y., Yu, L., Hu, K., Zhu, W., Tong, Q., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3912-9 · Cited by 78
Thamer, C., Machann, J., Stefan, N., Schäfer, S. A., Machicao, F., Staiger, H., Laakso, M., Böttcher, M., Claussen, C., Schick, F., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1209 · Cited by 76
“Therefore, PPAR- represents an interesting candidate mediator of metabolic disease and a promising target for its prevention and/or therapy (1).”
BackgroundResultInfluentialGirroir, E. E., Hollingshead, H. E., Billin, A. N., Willson, T. M., Robertson, G. P., Sharma, A. K., Amin, S., Gonzalez, F. J., & Peters, J. M. (2007) · Toxicology · doi:10.1016/j.tox.2007.10.023 · Cited by 78
“…ability to increase serum HDL cholesterol (Leibowitz et al. 2000; Oliver et al. 2001; Sprecher et al. 2006; van der Veen et al. 2005; Wallace et al. 2005), increase fatty acid catabolism in skeletal muscle, improve insulin resistance and inhibit inflammation (reviewed in (Barish et al. 2006)).”
BackgroundPPARδ regulates satellite cell proliferation and skeletal muscle regeneration
Angione, A. R., Jiang, C., Pan, D., Wang, Y.-X., & Kuang, S. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-33 · Cited by 62
“There are three PPAR isoforms (a, δ and g), and each plays a specific role in metabolism [22-24].”
BackgroundPeroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis
Han, X., Wu, Y., Yang, Q., & Cao, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107791 · Cited by 75
Lipids as targets for novel anti-inflammatory therapies
Huwiler, A., & Pfeilschifter, J. M. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.008 · Cited by 74
Transcriptional Profiling Identifies Functional Interactions of TGFβ and PPARβ/δ Signaling
Kaddatz, K., Adhikary, T., Finkernagel, F., Meissner, W., MÜller-BrÜsselbach, S., & MÜller, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.142018 · Cited by 66
Kino, T., Rice, K. C., & Chrousos, G. P. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01796.x · Cited by 73
Yue, T., Nerurkar, S. S., Bao, W., Jucker, B. M., Sarov‐Blat, L., Steplewski, K. M., Ohlstein, E. H., & Willette, R. N. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.135327 · Cited by 73
“This is an important consideration because PPAR- activators are in development for the treatment of dyslipidemia, obesity, and/or insulin resistance in patients with this metabolic syndrome, a population known to have an elevated risk of ischemic heart disease (Barish et al., 2006).”
BackgroundFatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD
Allison, M., Griffin, J., Vacca, M., & Vidal-Puig, A. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562945 · Cited by 63
Endocannabinoids, Adipose Tissue and Lipid Metabolism
Pagano, C., Rossato, M., & Vettor, R. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01690.x · Cited by 56
Balakumar, P., Kaur, T., & Singh, M. (2007) · Toxicology · doi:10.1016/j.tox.2007.12.011 · Cited by 71
“PPAR is ubiquitously expressed (Barish et al., 2006).”
Lipid‐sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome
Vacca, M., Degirolamo, C., Mariani‐Costantini, R., Palasciano, G., & Moschetta, A. (2011) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.137 · Cited by 63
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0219-5 · Cited by 71
van Beekum, O., Brenkman, A. B., Grøntved, L., Hamers, N., van den Broek, N. J. F., Berger, R., Mandrup, S., & Kalkhoven, E. (2007) · Endocrinology · doi:10.1210/en.2007-0977 · Cited by 71
Chen, J., Tian, J., Ge, H., Liu, R., & Xiao, J. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.12.017 · Cited by 69
Cantó, C., Pich, S., Paz, J. C., Sanches, R., Martínez, V., Orpinell, M., Palacín, M., Zorzano, A., & Gumà, A. (2007) · Diabetes · doi:10.2337/db06-1726 · Cited by 57
Ali, F., Ali, N. S., Bauer, A., Boyle, J. J., Hamdulay, S., Haskard, D. O., RANDI, A. M., & Mason, J. C. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp365 · Cited by 68
TNF-α inhibits PPARβ/δ activity and SIRT1 expression through NF-κB in human adipocytes
Serrano, L., Chacón, M. R., Maymó‐Masip, E., Barroso, E., Salvadó, L., Wabitsch, M., Garrido‐Sánchez, L., Tinahones, F. J., Palomer, X., Vendrell, J. J., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.05.006 · Cited by 68
Alqahtani, S., & Mahmoud, A. M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/4016209 · Cited by 68
Gani, O. A. B. S. M., & Sylte, I. (2008) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2008.04.008 · Cited by 67
PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home
Billin, A. N. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1465 · Cited by 57
Jiménez, R., Sánchez, M., Zarzuelo-Romero, M. J., Romero, M., Quintela, A. M., López-Sepúlveda, R., Galindo, P., Gómez‐Guzmán, M., Haro, J. M., Zarzuelo, A., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.159806 · Cited by 66
“PPAR- ligands have been more recently developed and are currently in clinical trials for the treatment of dyslipidemia (Barish et al., 2006; Risérus et al., 2008).”
MethodTranscriptional regulation of phosphatidylcholine biosynthesis
Sugimoto, H., Banchio, C., & Vance, D. E. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.01.002 · Cited by 66
Tsika, R. W., Schramm, C., Simmer, G., Fitzsimons, D. P., Moss, R. L., & Ji, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807461200 · Cited by 65
PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells
Rogue, A., Anthérieu, S., Vluggens, A., Umbdenstock, T., Claude, N., de la Moureyre-Spire, C., Weaver, R. J., & Guillouzo, A. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.02.001 · Cited by 65
Peroxisome proliferator-activated receptors: Bridging metabolic syndrome with molecular nutrition
Guri, A. J., Hontecillas, R., & Bassaganya-Riera, J. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.08.006 · Cited by 66
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases
Maccallini, C., Mollica, A., & Amoroso, R. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0220-9 · Cited by 65
PPARs and the orchestration of metabolic fuel selection
Sugden, M. C., Zariwala, M. G., & Holness, M. J. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.03.014 · Cited by 64
Retinoid metabolism and its effects on the vasculature
Rhee, E., Nallamshetty, S., & Plutzky, J. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.07.001 · Cited by 64
Association of a PPARD polymorphism with human physical performance
Ahmetov, I. I., Astratenkova, I. V., & Rogozkin, V. A. (2007) · Molecular Biology · doi:10.1134/s002689330705010x · Cited by 64
“The PPAR δ ligands include saturated and polyunsaturated fatty acids, synthetic and endogenous eicosanoids, and the agonists GW742 and GW501516, which are currently undergoing extensive clinical trials in patients with obesity, type II diabetes mellitus, and atherosclerosis [3].”
BackgroundXiao, L., Dong, J., Teng, X., Jin, S., Xue, H., Liu, S., Guo, Q., Shen, W., Ni, X., & Wu, Y. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001605 · Cited by 63
Higashiyama, H., Billin, A. N., Okamoto, Y., Kinoshita, M., & Asano, S. (2007) · Histochemistry and Cell Biology · doi:10.1007/s00418-007-0279-5 · Cited by 63
“The third member of the family, PPARdelta has been identiWed as a key metabolic regulator in several tissues including fat, skeletal muscle, and the heart (Barish et al. 2006; Evans et al. 2004).”
BackgroundMuscle insulin resistance: a case of fat overconsumption, not mitochondrial dysfunction
Kraegen, E. W., Cooney, G. J., & Turner, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803901105 · Cited by 62
Pharmacological agents for NASH
Ratziu, V. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.193 · Cited by 62
Exercise Pills: At the Starting Line
Li, S., & Laher, I. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.014 · Cited by 62
LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes
Kelly, K. J., Wu, P., Patterson, C. E., Temm, C. J., & Dominguez, J. H. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00396.2007 · Cited by 62
In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
He, B. K., Ning, Z. Q., Li, Z. B., Shan, S., Pan, D. S., Ko, B. C. B., Li, P. P., Shen, Z. F., Dou, G. F., Zhang, B. L., et al. (2012) · PPAR Research · doi:10.1155/2012/546548 · Cited by 53
“First, chiglitazar more significantly up-regulated the expression of PPARα and/or PPARδ downstream genes involved in the key processes of lipid metabolism and thermogenesis [4, 6], including SRA, CPT-1a, and CPT-1b from the investigated cell lines and PPARα, VLCS, and UCP1 in adipose tissue from diabetic mouse models.”
BackgroundMethodPPARs and their Effects on the Cardiovascular System
Oyekan, A. (2011) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2010.531845 · Cited by 61
Potthoff, M. J., Olson, E. N., & Bassel‐Duby, R. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282efb761 · Cited by 61
Gani, O. A. B. S. M. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-6 · Cited by 61
Rudolph, J., Chen, L., Majumdar, D., Bullock, W. H., Burns, M. G., Claus, T. H., Cruz, F. E. D., Daly, M., Ehrgott, F. J., Johnson, J. S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061299k · Cited by 60
PPARs in Bone: The Role in Bone Cell Differentiation and Regulation of Energy Metabolism
Lecka‐Czernik, B. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0016-1 · Cited by 60
Yuan, H., Lu, J., Xiao, J., Upadhyay, G., Umans, R., Kallakury, B., Yin, Y., Fant, M. E., Kopelovich, L., & Glazer, R. I. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0322 · Cited by 60
Rachid, T. L., Silva-Veiga, F. M., Graus‐Nunes, F., Bringhenti, I., Mandarim‐de‐Lacerda, C. A., & Souza‐Mello, V. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191365 · Cited by 60
Exploration of PPAR functions by microarray technology—A paradigm for nutrigenomics
Bünger, M., Hooiveld, G. J. E. J., Kersten, S., & Müller, M. M. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.004 · Cited by 60
Metadata
- Authors
- Barish, G. D.
- Affiliations
- Salk Institute for Biological Studies (US)
- Corresponding author
- Barish, G. D.
- ORCID
- Barish, G. D.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-03-01
- Volume
- 116
- Issue
- 3
- Pages
- 590-597
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1386117
- OpenAlex
- W1987601141
- Cited by
- 641
- References
- 100
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 16 · 2023: 7 · 2022: 12 · 2021: 9 · 2020: 23 · 2019: 15 · 2018: 24 · 2017: 26 · 2016: 28 · 2015: 29 · 2014: 31 · 2013: 39 · 2012: 46
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- March of Dimes Foundation
- Larry L. Hillblom Foundation
- National Institutes of Health (U19DK62434)
- University of California, San Diego
- National Heart, Lung, and Blood Institute (P50HL56989, P50HL056989)
- National Institute of Diabetes and Digestive and Kidney Diseases (U19 DK-62434, U19DK062434, F32DK071478)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- PPARδ, PPARα, PPARγ, metabolic syndrome, insulin resistance, hypertriglyceridemia, obesity, fatty acid degradation, adipose tissue, skeletal muscle, macrophage inflammation, atherosclerosis, nuclear receptors, weight gain, physical endurance
- MeSH terms
- Animals, Humans, Myocardium, Muscle, Skeletal, Metabolic Syndrome, PPAR delta, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.